DNCB and PPD skin testing in breast cancer.

DNCB and PPD skin testing was performed in 152 breast cancer patients. Bates' instruction with a plea for uniformity was used (Cancer, 43, 1979, 2306). Majority of patients were tested while being diagnosed and prior to the treatment.

Evaluation of the LAI test in patients with benign and malignant breast diseases.

Tumor "specific" immune recognition was assayed in 125 patients with various breast diseases including breast cancer of clinical stage I and II, 22 patients with other malignancies and 64 healthy persons employing leukocyte adherence inhibition test (LAI). In the group of breast cancer patients (BC) there were 81% of positive responders (52/65) with a mean nonadherence index (NAI) value 67.4.

Leukocyte adherence inhibition responses obtained with various tumor extracts in breast cancer patients.

Leukocyte adherence inhibition (LAI) assay was employed to detect cell-mediated immune response in breast cancer patients of clinical stages I and II. Twenty-one breast cancer extracts were screened in 232 breast cancer patients and 343 healthy persons. The activity of individual extracts differed remarkably.